Article: WellGen, Inc. Receives Investment from Amphion Capital Partners LLC; Amphion's CEO, Richard C. E. Morgan, to Join WellGen Board.

Business Editors/Health/Medical Writers

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--March 24, 2004

WellGen, Inc., a biotechnology company using nutragenomics to develop wellness products from plants that alter the expression of genes responsible for human disease, announced today that it has received $3 million in the form of equity capital, through a private offering of preferred stock, from venture-capital investors led by Amphion Capital Partners LLC. The funding will enable WellGen to introduce its first product, currently in clinical trials, and to advance other identified compounds to the human clinical trial stage, as well as to identify additional ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!